BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 10602413)

  • 1. Leukemogenesis by CBF oncoproteins.
    Friedman AD
    Leukemia; 1999 Dec; 13(12):1932-42. PubMed ID: 10602413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1.
    Tanaka K; Tanaka T; Kurokawa M; Imai Y; Ogawa S; Mitani K; Yazaki Y; Hirai H
    Blood; 1998 Mar; 91(5):1688-99. PubMed ID: 9473235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
    Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
    Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F; Pisegna S; Diverio D
    Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominant-negative CBF - a model for overcoming inhibition of proliferation by CBF oncoproteins.
    Lou J; Cao W; Bernardin F; Ayyanathan K; RauscherIII FJ; Friedman AD
    Oncogene; 2000 May; 19(22):2695-703. PubMed ID: 10851069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AML1/CBFbeta transcription complex: its role in normal hematopoiesis and leukemia.
    Downing JR
    Leukemia; 2001 Apr; 15(4):664-5. PubMed ID: 11368373
    [No Abstract]   [Full Text] [Related]  

  • 7. Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias.
    Tanaka T; Mitani K; Kurokawa M; Ogawa S; Tanaka K; Nishida J; Yazaki Y; Shibata Y; Hirai H
    Mol Cell Biol; 1995 May; 15(5):2383-92. PubMed ID: 7739522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family.
    Fears S; Mathieu C; Zeleznik-Le N; Huang S; Rowley JD; Nucifora G
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1642-7. PubMed ID: 8643684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.
    Cuenco GM; Ren R
    Oncogene; 2001 Dec; 20(57):8236-48. PubMed ID: 11781838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Core-binding factor beta (CBFbeta), but not CBFbeta-smooth muscle myosin heavy chain, rescues definitive hematopoiesis in CBFbeta-deficient embryonic stem cells.
    Miller JD; Stacy T; Liu PP; Speck NA
    Blood; 2001 Apr; 97(8):2248-56. PubMed ID: 11290585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies.
    Zent C; Rowley JD; Nucifora G
    Leukemia; 1997 Apr; 11 Suppl 3():273-8. PubMed ID: 9209363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of AML1/Runx1 in the pathogenesis of hematological malignancies.
    Kurokawa M; Hirai H
    Cancer Sci; 2003 Oct; 94(10):841-6. PubMed ID: 14556655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice.
    Cuenco GM; Ren R
    Oncogene; 2004 Jan; 23(2):569-79. PubMed ID: 14724585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular pathogenesis of leukemias].
    Kurokawa M
    Rinsho Ketsueki; 2009 Oct; 50(10):1382-8. PubMed ID: 19915346
    [No Abstract]   [Full Text] [Related]  

  • 15. AML1 interconnected pathways of leukemogenesis.
    Michaud J; Scott HS; Escher R
    Cancer Invest; 2003; 21(1):105-36. PubMed ID: 12643014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1.
    Sood R; Talwar-Trikha A; Chakrabarti SR; Nucifora G
    Leukemia; 1999 Mar; 13(3):348-57. PubMed ID: 10086725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the AML1 transcription factor in leukemogenesis.
    Lorsbach RB; Downing JR
    Int J Hematol; 2001 Oct; 74(3):258-65. PubMed ID: 11721960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The EVI1 gene in myeloid leukemia.
    Nucifora G
    Leukemia; 1997 Dec; 11(12):2022-31. PubMed ID: 9447815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis of the t(8;21) translocation in acute myeloid leukaemia.
    Ohki M
    Semin Cancer Biol; 1993 Dec; 4(6):369-75. PubMed ID: 8142622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML.
    Cuenco GM; Nucifora G; Ren R
    Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1760-5. PubMed ID: 10677531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.